Coherus announced it is launching YUSIMRY® (adalimumab-aqvh) biosimilar to AbbVie’s Humira®, in July 2023 with a list price of $995 per carton. This is the lowest price announced of any adalimumab product in the US, and represents an 85% discount on the originator product.
On the same day, Coherus also announced a partnership with Mark Cuban Cost Plus Drug Company (MCCPDC) to offer MCCPDC customers YUSIMRY® in July 2023 for $569.27 plus dispensing and shipping fees.
YUSIMRY® was approved by the FDA in December 2021 indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. As the AbbVie global Humira® (adalimumab) empire crumbles, Samsung Bioepis/Merck has the next licensed launch date in the US on 30 June this year, and the next day (1 July) the following biosimilar entities are licensed launch: Alvotech, Celltrion, Boehringer Ingelheim, Coherus before Fresenius Kabi in July (on an unspecified date), Mylan/Viatris on 31 July 2023, Sandoz on 30 September 2023, Momenta and Pfizer on 20 November 2023.Print Page Mail Article